Antihemophilic Factor (Recombinant) ( DrugBank: - )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
288自己免疫性後天性凝固因子欠乏症2

288. 自己免疫性後天性凝固因子欠乏症

臨床試験数 : 206 /  薬物数 : 231 - (DrugBank : 28) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 21
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02932618
(ClinicalTrials.gov)		December 18, 201712/10/2016A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand DiseaseVon Willebrand DiseaseBiological: von Willebrand factor (Recombinant);Biological: Antihemophilic Factor (Recombinant)Baxalta now part of ShireTakeda Development Center Americas, Inc.RecruitingN/A17 YearsAll34Phase 3United States;Austria;Belgium;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom
2NCT02973087
(ClinicalTrials.gov)		November 16, 201722/11/2016rVWF IN PROPHYLAXISA PROSPECTIVE, PHASE 3, OPEN-LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASEVon Willebrand DiseaseBiological: von Willebrand factor (Recombinant);Biological: Antihemophilic Factor (Recombinant)TakedaBaxalta Innovations GmbH, now part of ShireCompleted18 YearsN/AAll29Phase 3United States;Canada;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey